Perspective Therapeutics
CATX
57 hedge funds and large institutions have $20.2M invested in Perspective Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 16 increasing their positions, 4 reducing their positions, and 8 closing their positions.
390% more capital invested
Capital invested by funds: $4.12M → $20.2M (+$16.1M)
300% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 4
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
33% more funds holding
Funds holding: 43 → 57 (+14)
0.33% more ownership
Funds ownership: 0.99% → 1.31% (+0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.16M |
| 2 |
Renaissance Technologies
New York
|
+$2.89M |
| 3 |
BlackRock
New York
|
+$2.85M |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$1.36M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$998K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$87K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$74.2K |
| 3 |
VF
Virtu Financial
New York
|
-$72.3K |
| 4 |
Squarepoint
New York
|
-$54K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$53.8K |
CATX Hedge Fund Activity: Q1 2021 in Review
57 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q1 2021, worth a combined $20.2M — up 390% from $4.12M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CATX positions and 8 closed out — a net gain of 14 holders — while 16 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.16M. The largest seller was Anson Funds Management, exiting entirely with an estimated $87K sold.
- 57 institutional investors held Perspective Therapeutics (CATX) as of Q1 2021, up from 43 in Q4 2020.
- Funds reported $20.2M of Perspective Therapeutics stock for Q1 2021, up 390% quarter-over-quarter.
- 22 funds opened new Perspective Therapeutics positions in Q1 2021 and 8 closed out, a net change of +14 holders.
- The largest Perspective Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $5.16M added.
- The largest Perspective Therapeutics seller in Q1 2021 was Anson Funds Management, an estimated $87K sold.
Based on aggregated 13F filings for Q1 2021.